Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

RMD

Analysis of ResMed Stock Performance

Shares of Health Care sector company ResMed moved -6.3% today, and are now trading at a price of $190.7. The Large-Cap stock's daily volume was 2,153,599 compared to its average volume of 1,198,390. The S&P 500 index returned a 0.0% performance.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company is based in San Diego and has 10,600 full time employees. Its market capitalization is $27,662,252,032. ResMed currently offers its equity investors a dividend that yields 1.1% per year.

15 analysts are following ResMed and have set target prices ranging from $180.0 to $340.0 per share. On average, they have given the company a rating of buy. At today's prices, RMD is trading -29.53% away from its average analyst target price of $270.6 per share.

Over the last year, RMD shares have gone down by -16.9%, which represents a difference of -44.8% when compared to the S&P 500. The stock's 52 week high is $293.81 per share and its 52 week low is $190.4. With average free cash flows of $849.07 Million that have been growing at an average rate of 19.9% over the last 5 years, ResMed declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2025 1,751,588 89,865 1,661,723 27.65
2024 1,401,260 99,460 1,301,800 126.94
2023 693,299 119,672 573,627 165.19
2022 351,147 134,835 216,312 -65.88
2021 736,718 102,712 634,006 -10.31
2020 802,255 95,330 706,925
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS